Oncologists are treating nearly twice as many patients with cell and gene therapies (CGTs) as they were in 2024, and 97% say CGTs could offer some patients the best chance for a cure. This year, the ...

Biologics by McKesson combines technology, clinical expertise and personalized support to help patients access and understand increasingly complex specialty therapies. This Always Advancing episode ...

Start with what you know right now, even before every detail is final. Leaders should talk with finance and adjacent teams to separate decisions that need certainty from the work that holds value ...

Over the last 20 years, McKesson has been advancing cancer care by empowering community providers to maintain their independence so patients can get high-quality care closer to home, while partnering ...

These efforts reflect a shared commitment to apply AI thoughtfully to reduce complexity and strengthen the systems patients rely on. The healthcare system’s intricate web of tasks and processes often ...

As therapies grow more complex and regulatory requirements evolve, providers, pharmacies and patients need a supply chain that can keep pace, manage specialized therapies and support continuity of ...

Pharmacies operate within a complex environment of contracts, credentialing requirements, rules and reimbursement systems that few outside the industry ever see. Pharmacy Services Administrative ...

At LogiPharma USA 2026, McKesson leaders Chris Van Norman and Nicole Wade participated in the panel, “Racing to Meet the Moment: Supply Chains Built for Today’s Therapies.” The discussion highlighted ...

Consolidated revenues of $97.8 billion increased 23%. Earnings per diluted share of $6.25 decreased $0.75. Adjusted Earnings per Diluted Share of $8.26 increased 5%. McKesson completed the ...

McKesson is investigating a cybersecurity incident involving third-party applications and unauthorized access and exfiltration of data. McKesson supplies medical equipment, pharmaceuticals, and health ...

IRVING, Texas, November 5, 2025 - McKesson Corporation (NYSE:MCK) today announced results for the second quarter ended September 30, 2025. Quarterly consolidated revenues increased to a record high of ...

IRVING, Texas, August 25, 2026—McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global ...